Targeting MET and EGFR in NSCLC—what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?

Por Charakidis, Michail, Boyer, Michael
Publicado no Transl Lung Cancer Res (2014)

Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine...

Por Economopoulou, Panagiota, Mountzios, Giannis
Publicado no Transl Lung Cancer Res (2016)

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Por Villadolid, Jeryl, Amin, Asim
Publicado no Transl Lung Cancer Res (2015)

Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance

Por Villadolid, Jeryl, Ersek, Jennifer L., Fong, Mei Ka, Sirianno, Lindsey, Story, Ellen S.
Publicado no Transl Lung Cancer Res (2015)

Effects of etomidate and propofol on immune function in patients with lung adenocarcinoma

Por Liu, Jiapeng, Dong, Wei, Wang, Tao, Liu, Liang, Zhan, Long, Shi, Yifei, Han, Jiange
Publicado no Am J Transl Res (2016)

Pre-operative chemotherapy for non-small cell lung carcinoma

Por Horita, Nobuyuki, Woo, Tetsukan, Miyazawa, Naoki, Kaneko, Takeshi
Publicado no Transl Lung Cancer Res (2015)

P30. Ki-67 expression in lung carcinoid tumors

Por Budimir, Bernard, Kukulj, Suzana, Brcic, Luka, Opasic, Luka, Cucevic, Branka, Serdarevic, Marina, Drpa, Gordana, Sovic, Slavica
Publicado no Transl Lung Cancer Res (2014)

Stem cells and cell therapy approaches in lung biology and diseases

Por Sueblinvong, Viranuj, Weiss, Daniel J.
Publicado em 2010

Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond

Por Khoo, Christine, Rogers, Toni-Maree, Fellowes, Andrew, Bell, Anthony, Fox, Stephen
Publicado no Transl Lung Cancer Res (2015)

Activated RET and ROS: two new driver mutations in lung adenocarcinoma

Por Bos, Marc, Gardizi, Masyar, Schildhaus, Hans-Ulrich, Buettner, Reinhard, Wolf, Juergen
Publicado no Transl Lung Cancer Res (2013)

O13. Subtype-specific KRAS mutations in advanced lung adenocarcinoma

Por Lohinai, Zoltan, Cserepes, Mihaly, Ostoros, Gyula, Moldvay, Judit, Ghanim, Bahil, Laszlo, Viktoria, Hoda, Mir Alireza, Klepetko, Walter, Hegedus, Balazs, Dome, Balazs
Publicado no Transl Lung Cancer Res (2014)

P26. Well differentiated neuroendocrine tumors of the lung—our experience

Por Kulísková, Jana, Fischer, Ondrej, Kultan, Juraj, Polášek, Vladan, Grygárková, Ivona, Kolek, Vitezslav, Tichý, Tomáš
Publicado no Transl Lung Cancer Res (2014)

FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications

Por Schildhaus, Hans-Ulrich, Nogova, Lucia, Wolf, Jürgen, Buettner, Reinhard
Publicado no Transl Lung Cancer Res (2013)

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter...

Por Yoshida, Kazushi, Yamada, Yasuhide
Publicado no Transl Lung Cancer Res (2015)

What do we know about ground-glass opacity nodules in the lung?

Por Lee, Choon-Taek
Publicado no Transl Lung Cancer Res (2015)

Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung

Por McIntire, Maria G, Santagata, Sandro, Ligon, Keith, Chirieac, Lucian R
Publicado em 2010

Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials

Por Osarogiagbon, Raymond U., Cappuzzo, Federico, Ciuleanu, Tudor, Leon, Larry, Klughammer, Barbara
Publicado no Transl Lung Cancer Res (2015)

Impact of dose calculation models on radiotherapy outcomes and quality adjusted life years for lung...

Por Chaikh, Abdulhamid, Docquière, Nicolas, Bondiau, Pierre-Yves, Balosso, Jacques
Publicado no Transl Lung Cancer Res (2016)

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Por Domagala-Kulawik, Joanna
Publicado no Transl Lung Cancer Res (2015)

The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor...

Por Zou, Qian, Zhan, Ping, Lv, Tangfeng, Song, Yong
Publicado no Transl Lung Cancer Res (2015)